Olema Pharmaceuticals (OLMA) Operating Income (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Operating Income of -$58.0 million for Q1 2026, down 66.28% year-over-year from -$172.0 million in Q1 2025, and down 15.78% quarter-over-quarter from -$50.1 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Operating Income (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Operating Income data on file, last reported at -$58.0 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$58.0 million, down 66.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$201.8 million (down 41.33% YoY), and the FY2025 annual result was -$178.7 million, down 25.62% from the prior year.
- Operating Income retreated to -$58.0 million in Q1 2026 per OLMA's latest filing, from -$50.1 million in the prior quarter.
- Over five years, Operating Income peaked at -$21.6 million in Q2 2023 and troughed at -$58.0 million in Q1 2026.
- A 5-year average of -$34.8 million and a median of -$33.5 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income sank 101.51% in 2022, then jumped 35.12% in 2023.
- A 5-year view of Operating Income shows it stood at -$27.2 million in 2022, then decreased by 11.75% to -$30.4 million in 2023, then fell by 20.88% to -$36.8 million in 2024, then slumped by 36.22% to -$50.1 million in 2025, then dropped by 15.78% to -$58.0 million in 2026.
- Business Quant data shows OLMA's Operating Income at -$58.0 million in Q1 2026, -$50.1 million in Q4 2025, and -$45.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -65.83 Mn |
| 10 | Olema Pharmaceuticals | 1.08 Bn | 1.08 Bn | - | -57.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.99 Mn |
| Dec 31, 2025 | -50.08 Mn |
| Sep 30, 2025 | -45.88 Mn |
| Jun 30, 2025 | -47.86 Mn |
| Mar 31, 2025 | -34.87 Mn |
| Dec 31, 2024 | -36.77 Mn |
| Sep 30, 2024 | -37.62 Mn |
| Jun 30, 2024 | -33.53 Mn |
| Mar 31, 2024 | -34.34 Mn |
| Dec 31, 2023 | -30.42 Mn |
| Sep 30, 2023 | -23.34 Mn |
| Jun 30, 2023 | -21.60 Mn |
| Mar 31, 2023 | -29.60 Mn |
| Dec 31, 2022 | -27.22 Mn |
| Sep 30, 2022 | -23.22 Mn |
| Jun 30, 2022 | -33.29 Mn |
| Mar 31, 2022 | -23.25 Mn |
| Dec 31, 2021 | -21.76 Mn |
| Sep 30, 2021 | -17.76 Mn |
| Jun 30, 2021 | -16.52 Mn |